Evaxion to Showcase Advanced AI Vaccine Technology at Congress
Evaxion Biotech to Present at the World Vaccine Congress
COPENHAGEN, Denmark - Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage TechBio company, is gearing up to present at the upcoming World Vaccine Congress. Mark your calendars for this important event taking place from April 21-24, where industry leaders converge to discuss pioneering advancements in vaccine technologies.
Innovative Presentations Highlighting AI-Driven Solutions
Evaxion takes pride in its cutting-edge AI-Immunology™ platform, which plays a pivotal role in the development of vaccines. During the conference, two key team members will showcase the company's innovative efforts in vaccine development:
Presentation on Cancer Vaccines
Birgitte Rønø, the Chief Scientific Officer at Evaxion, will delve into how the company utilizes its AI-Immunology™ technology for target discovery in cancer vaccines. This presentation aims to shed light on new approaches in cancer immunotherapy that can potentially offer more personalized treatment options to patients.
Focus on Infectious Diseases
Pär Comstedt, Vice President of Infectious Disease Vaccine Development, will discuss the application of AI in discovering targets for vaccines aimed at combating infectious diseases. This talk underscores the significance of leveraging advanced technology to address urgent health challenges presented by emerging and re-emerging diseases.
Networking Opportunities for Collaborations
In addition to the presentations, Evaxion invites attendees to visit booth #351 throughout the Congress. Here, representatives will engage in discussions regarding effective and precise target discovery facilitated by their AI-Immunology™ platform, alongside insights into their pipeline of vaccine candidates targeting various cancers and infectious diseases.
Detailed Presentation Scheduling
Details regarding the presentations are as follows:
AI-Powered Antigen Target Discovery for Cancer Vaccines
Location: Room 206
Date/Time: April 23 at 11:40 ET/17:40 CET
Presenter: Birgitte Rønø
AI-Powered Target Discovery for Infectious Disease Vaccines
Location: Room 202b
Date/Time: April 23 at 15:10 ET/21:10 CET
Presenter: Pär Comstedt
Contact Information for Inquiries
For any inquiries or further information about Evaxion's work, please reach out to:
Evaxion Biotech A/S
Mads Kronborg
Vice President, Investor Relations & Communication
Phone: +45 53 54 82 96
About Evaxion Biotech A/S
Evaxion Biotech A/S is revolutionizing immunotherapy through AI technology. The company's AI-Immunology™ platform is designed to decode immune responses and drive the development of breakthrough therapies for cancers and infectious diseases. With a strong pipeline of personalized vaccines, Evaxion is poised to make significant contributions in the healthcare sector.
Frequently Asked Questions
What is the main focus of Evaxion's presentations at the Congress?
Evaxion will showcase its AI-Immunology™ platform's applications in both cancer and infectious disease vaccine development.
Who will be presenting on behalf of Evaxion?
Birgitte Rønø, Chief Scientific Officer, and Pär Comstedt, VP of Infectious Disease Vaccine Development, will deliver the presentations.
Why is the World Vaccine Congress important for Evaxion?
This Congress serves as an opportunity to network with potential partners and showcase innovative solutions that can redefine vaccine strategies globally.
Where can attendees find Evaxion at the Congress?
Visitors are encouraged to stop by booth #351 for discussions about the company's AI-Immunology™ platform and vaccine candidates.
What are the key diseases Evaxion targets with its vaccines?
Evaxion is focused on developing vaccines for various cancers as well as infectious diseases driven by its AI technology.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
